Yang Suhui, Jackson Chanel, Karapetyan Eduard, Dutta Pranabananda, Kermah Dulcie, Wu Yong, Wu Yanyuan, Schloss John, Vadgama Jaydutt V
Division of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
School of Pharmacy, American University of Health Sciences, Signal Hill, CA 90755, USA.
Cancers (Basel). 2022 Jan 31;14(3):745. doi: 10.3390/cancers14030745.
Protein disulfide isomerase (PDI) is the endoplasmic reticulum (ER)'s most abundant and essential enzyme and serves as the primary catalyst for protein folding. Due to its apparent role in supporting the rapid proliferation of cancer cells, the selective blockade of PDI results in apoptosis through sustained activation of UPR pathways. The functions of PDI, especially in cancers, have been extensively studied over a decade, and recent research has explored the use of PDI inhibitors in the treatment of cancers but with focus areas of other cancers, such as brain or ovarian cancer. In this review, we discuss the roles of PDI members in breast cancer and PDI inhibitors used in breast cancer research. Additionally, a few PDI members may be suggested as potential molecular targets for highly metastatic breast cancers, such as TNBC, that require more attention in future research.
蛋白质二硫键异构酶(PDI)是内质网(ER)中含量最丰富且必不可少的酶,是蛋白质折叠的主要催化剂。由于其在支持癌细胞快速增殖方面的明显作用,选择性阻断PDI会通过持续激活未折叠蛋白反应(UPR)途径导致细胞凋亡。十多年来,人们广泛研究了PDI的功能,尤其是在癌症中的功能,最近的研究探索了使用PDI抑制剂治疗癌症,但重点是其他癌症领域,如脑癌或卵巢癌。在本综述中,我们讨论了PDI成员在乳腺癌中的作用以及用于乳腺癌研究的PDI抑制剂。此外,一些PDI成员可能被认为是高转移性乳腺癌(如三阴性乳腺癌(TNBC))的潜在分子靶点,在未来的研究中需要更多关注。